Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Celldex Therapeutics Inc
CLDX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$29.67
2.14
7.77%
Dern. MÀJ: Oct 19, 4:00 PM
$29.67
2.14
7.77%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Celldex Therapeutics Financials
Celldex Therapeutics (CLDX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.20) by 1.67 percent. This is a 45.68 percent decrease over losses of $(0.81) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q4 EPS $(1.22) Misses $(1.00) Estimate, Sales $100.000K Miss $1.477M Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.00) by 21.88 percent. This is a 71.83 percent decrease over losses of $(0.71) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q2 EPS $(0.85) Misses $(0.83) Estimate, Sales $730.000K Miss $1.007M Estimate
Benzinga Newsdesk
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
Avi Kapoor
